Platelet Count to Spleen Diameter Ratio for the Diagnosis of Gastroesophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis

Table 2

Results of meta-analyses in subgroups for any varices.

Groups	AUSROC	Sensitivity (95% CI)	Specificity (95% CI)	PLR (95% CI)	NLR (95% CI)	DOR (95% CI)
Threshold of 909	0.8867	0.84 (0.82–0.86)	0.80 (0.78–0.82)	3.95 (2.66–5.86)	0.21 (0.13–0.32)	25.06 (11.84–53.03)
Patients with viral hepatitis	0.8675	0.92 (0.90–0.94)	0.78 (0.74–0.81)	3.80 (2.04–7.08)	0.11 (0.06–0.23)	37.76 (14.43–98.84)
High quality studies	0.876	0.84 (0.81–0.87)	0.77 (0.74–0.8)	3.64 (2.11–6.3)	0.15 (0.07–0.33)	23.79 (10.35–54.7)
Prospective studies	0.8748	0.86 (0.84–0.88)	0.76 (0.73–0.79)	3.59 (2.39–5.39)	0.12 (0.07–0.22)	33.85 (15.67–73.15)
Region
Europe	0.8289	0.83 (0.8–0.86)	0.65 (0.61–0.7)	2.58 (1.81–3.69)	0.2 (0.11–0.38)	15.46 (7.07–33.79)
Asia	0.9195	0.86 (0.84–0.87)	0.86 (0.84–0.88)	5.18 (3.5–7.65)	0.11 (0.06–0.2)	55.48 (24.27–126.81)
Africa	0.8537	0.87 (0.84–0.9)	0.71 (0.64–0.77)	3.28 (1.74–6.16)	0.16 (0.08–0.34)	23.31 (9.2–59.09)
North America	NA	0.82 (0.75–0.88)	0.67 (0.56–0.77)	2.45 (1.76–3.4)	0.27 (0.18–0.39)	9.06 (4.73–17.36)
Sample size
<100	0.7895	0.81 (0.77–0.84)	0.7 (0.65–0.75)	2.57 (2.01–3.3)	0.25 (0.15–0.4)	12.58 (6.34–24.97)
≥100	0.9012	0.85 (0.83–0.86)	0.79 (0.77–0.81)	4.1 (2.92–5.77)	0.14 (0.09–0.22)	34.51 (18.84–63.2)
Prevalence of varices
<50%	0.8804	0.91 (0.88–0.93)	0.86 (0.83–0.88)	5.29 (3.03–9.23)	0.11 (0.04–0.3)	54.16 (14.29–205.25)
≥50%	0.8633	0.83 (0.81–0.84)	0.73 (0.7–0.75)	3.15 (2.45–4.05)	0.19 (0.13–0.26)	21.12 (12.85–34.71)

AUSROC, area under the summary receiver operating characteristic curves; CI, confidence interval; DOR, diagnostic odds ratios; NLR, negative likelihood ratio; PLR, positive likelihood ratio.